Tag:
Jazz Pharmaceuticals
Latest Headlines
Latest Headlines
Analysts track a spike in mid-cap biotechs' R&D spend
Analysts at GlobalData took a quarterly snapshot of the R&D expenses for a big batch of mid-cap biotechs and concluded that rising research costs were eroding corporate profitability. And they pinned the blame squarely on the pricey hunt for new cancer drugs.
Jazz strikes up a $120M Concert Pharma collaboration on next-gen Xyrem
Jazz Pharmaceuticals has stepped up to grab the worldwide rights to a tweaked version of the narcolepsy drug Xyrem from Lexington, MA-based Concert Pharmaceuticals, a biotech which has been making a splash with its deuterium-modification approach for next-gen therapeutics.
Jazz CFO joins Medivation's board of directors
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Jazz Pharma snaps up Eusa in $700M buyout deal
The Ireland-based drugmaker ($JAZZ) says it will shell out $650 million upfront and potentially $50 million more to scoop up Eusa Pharma and its drugs for cancer and critical care.
Jazz Pharmaceuticals announces another deal
Just months after completing a merger with Azur Pharma, Jazz has picked up specialty drugmaker Eusa Pharma for up to $700 million.
Jazz didn't notify FDA of 74 serious side-effect reports
The FDA has issued a stern warning to Jazz Pharmaceuticals ( $JAZZ ), saying the company failed to properly report serious side effects of its drugs. Jazz also failed to submit reports on 74 serious
Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition
Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ( $JAZZ ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire
Jazz shares hit sour note as FDA rejects fibromyalgia drug
The FDA has handed Jazz Pharmaceuticals a setback, spurning its application for a new therapy to treat fibromyalgia and sending the developer back to the drawing board for fresh data on JZP-6 that
Jazz fibromyalgia drug nixed by FDA panel
An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the
FDA panel nixes Jazz drug for fibromyalgia
An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the
